AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32366122 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive periacetabular osteotomy
Number of subjects: 64
Study 32366122 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 64
Study 32366324 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin infusion at 3 mL/kg over 30 min
Number of subjects: 30
Study 32366486 — intervention group
Group type: EXPERIMENTAL
Intervention: External heated humidification during non-invasive ventilation
Number of subjects: 0
Study 32366486 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heated humidification)
Number of subjects: 0
Study 32367136 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercisers (n=57)
Number of subjects: 177
Study 32367136 — intervention group
Group type: COMPARATOR
Intervention: Non-exercisers (n=120)
Number of subjects: 177
Study 32367136 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index between 25 and 29.9
Number of subjects: 177
Study 32367136 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index >30
Number of subjects: 177
Study 32367136 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically strenuous occupations
Number of subjects: 177
Study 32367609 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal acoustic reflectometry (AAR) before and after rectal distension with 100 ml of air
Number of subjects: 32
Study 32367616 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontally healthy individuals
Number of subjects: 750
Study 32367616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingivitis individuals
Number of subjects: 750
Study 32367616 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis individuals
Number of subjects: 750
Study 32367815 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily in combination with sofosbuvir 400 mg for 12 weeks
Number of subjects: 17
Study 32367815 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily
Number of subjects: 17
Study 32368162 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir 50 mg/100 mg once daily for 12 weeks
Number of subjects: 119
Study 32368162 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks followed by open-label elbasvir/grazoprevir for 12 weeks
Number of subjects: 119
Study 32368162 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir
Number of subjects: 119
Study 32368162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 32368217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy (ILIT) with a single preseason booster of 1000 SQ-U Alutard 5-grasses
Number of subjects: 0
Study 32368217 — intervention group
Group type: COMPARATOR
Intervention: Intralymphatic immunotherapy (ILIT) with standard dosing of 3000 SQ-U over 2 months
Number of subjects: 0
Study 32368624 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F] HX4 PET imaging during RTx
Number of subjects: 34
Study 32368624 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F] HX4 PET imaging with residual hypoxia (rHV)
Number of subjects: 34
Study 32368624 — intervention group
Group type: COMPARATOR
Intervention: Static [18F] HX4 PET imaging
Number of subjects: 34
Study 32368624 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in [18F] HX4 uptake
Number of subjects: 34
Study 32368692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (a β3AR agonist)
Number of subjects: 0
Study 32368692 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32368702 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic PVHR
Number of subjects: 100
Study 32368702 — intervention group
Group type: COMPARATOR
Intervention: Open PVHR
Number of subjects: 100
Study 32368713 — intervention group
Group type: EXPERIMENTAL
Intervention: self-management + text message program
Number of subjects: 100
Study 32368793 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 4507
Study 32368793 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT
Number of subjects: 4507
Study 32368793 — intervention group
Group type: EXPERIMENTAL
Intervention: MBT
Number of subjects: 4507
Study 32368961 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/MRI
Number of subjects: 56
Study 32368961 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body DW MRI
Number of subjects: 56
Study 32368963 — intervention group
Group type: EXPERIMENTAL
Intervention: CT metrics of emphysema, venous vascular volume, and sarcopenia
Number of subjects: 0
Study 32369480 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 40 mg daily for 3 days
Number of subjects: 10
Study 32369811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 113
Study 32369811 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Bypass (GB)
Number of subjects: 113
Study 32369811 — intervention group
Group type: COMPARATOR
Intervention: SG
Number of subjects: 113
Study 32369811 — intervention group
Group type: COMPARATOR
Intervention: GB
Number of subjects: 113
Study 32370248 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular free wall longitudinal strain (RV FWS)
Number of subjects: 0
Study 32370805 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel4Diabetes Healthy Diet Score
Number of subjects: 3268
Study 32370805 — intervention group
Group type: COMPARATOR
Intervention: Healthy Diet Score
Number of subjects: 3268
Study 32370854 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 154324
Study 32370854 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 154324
Study 32370854 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 154324
Study 32370854 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 154324
Study 32371459 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR5 blockade
Number of subjects: 1330
Study 32371459 — intervention group
Group type: COMPARATOR
Intervention: High CCR5 expression
Number of subjects: 1330
Study 32371510 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria control tools usage
Number of subjects: 48448
Study 32371510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-net usage
Number of subjects: 48448
Study 32371510 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient discharges due to malaria
Number of subjects: 48448
Study 32371510 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient discharges due to HIV
Number of subjects: 48448
Study 32371510 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient discharges due to anaemia
Number of subjects: 48448
Study 32371540 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib, 400 mg twice daily
Number of subjects: 165
Study 32371584 — intervention group
Group type: EXPERIMENTAL
Intervention: Prexasertib combined with cisplatin and radiation
Number of subjects: 0
Study 32371584 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and radiation alone
Number of subjects: 0
Study 32371667 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy for cancer
Number of subjects: 196
Study 32371667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea during treatment
Number of subjects: 196
Study 32371667 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anxiety
Number of subjects: 196
Study 32371667 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep
Number of subjects: 196
Study 32371667 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of nausea
Number of subjects: 196
Study 32371801 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 501
Study 32371801 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sedentary time
Number of subjects: 501
Study 32371801 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased obesity
Number of subjects: 501
Study 32371801 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased insulin resistance
Number of subjects: 501
Study 32371801 — intervention group
Group type: EXPERIMENTAL
Intervention: Having triglycerides above 150 mg/dl
Number of subjects: 501
Study 32371801 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity
Number of subjects: 501
Study 32371801 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased uric acid
Number of subjects: 501
Study 32371801 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance index homeostatic model assessment
Number of subjects: 501
Study 32371801 — intervention group
Group type: EXPERIMENTAL
Intervention: Less physical activity
Number of subjects: 501
Study 32371806 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive participants
Number of subjects: 535
Study 32371806 — intervention group
Group type: COMPARATOR
Intervention: Normotensive participants
Number of subjects: 535
Study 32372280 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 151
Study 32372294 — intervention group
Group type: EXPERIMENTAL
Intervention: ER ambroxol 75-mg retard capsules once daily
Number of subjects: 24
Study 32372294 — intervention group
Group type: COMPARATOR
Intervention: IR ambroxol 60-mg effervescent tablets twice daily
Number of subjects: 24
Study 32372294 — intervention group
Group type: COMPARATOR
Intervention: IR ambroxol 30-mg tablets twice daily
Number of subjects: 24
Study 32372382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 4849
Study 32372382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 4849
Study 32372382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4849
Study 32372382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin (both doses)
Number of subjects: 4849
Study 32372416 — intervention group
Group type: EXPERIMENTAL
Intervention: DLL3-targeting antibody-drug conjugate (Rovalpituzumab tesirine - Rova-T)
Number of subjects: 65
Study 32372416 — intervention group
Group type: COMPARATOR
Intervention: DLL3 expression
Number of subjects: 65
Study 32372672 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor, sintilimab, administered for three cycles.
Number of subjects: 1
Study 32373032 — intervention group
Group type: EXPERIMENTAL
Intervention: Online guided self-help intervention
Number of subjects: 99
Study 32373059 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor outcome measures, specific details not available
Number of subjects: 0
Study 32373171 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment with radon water
Number of subjects: 0
Study 32373366 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cervical spine stabilizer (ECS) training
Number of subjects: 40
Study 32373366 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 40
Study 32373649 — intervention group
Group type: EXPERIMENTAL
Intervention: rQNestin34.5v.2
Number of subjects: 0
Study 32373649 — intervention group
Group type: COMPARATOR
Intervention: cyclophosphamide (CPA)
Number of subjects: 0
Study 32374193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 0
Study 32374193 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32374423 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly injection of anti-VEGF agents (ranibizumab 0.5 mg, bevacizumab 1.25 mg, aflibercept 2.0 mg)
Number of subjects: 7732
Study 32374423 — intervention group
Group type: COMPARATOR
Intervention: Standard PRN regimen
Number of subjects: 7732
Study 32374423 — intervention group
Group type: COMPARATOR
Intervention: Treat-and-extend regimen
Number of subjects: 7732
Study 32374423 — intervention group
Group type: COMPARATOR
Intervention: Standard PRN treatment
Number of subjects: 7732
Study 32374423 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly injection
Number of subjects: 7732
Study 32374423 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly injections
Number of subjects: 7732
Study 32374423 — intervention group
Group type: COMPARATOR
Intervention: PRN regimens
Number of subjects: 7732
Study 32374423 — intervention group
Group type: COMPARATOR
Intervention: Extended-fixed regimen
Number of subjects: 7732
Study 32374423 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly group
Number of subjects: 7732
Study 32374423 — intervention group
Group type: COMPARATOR
Intervention: Extended-fixed group
Number of subjects: 7732
Study 32374868 — intervention group
Group type: EXPERIMENTAL
Intervention: Post gadolinium arterial wall enhancement (AWE) on MRI
Number of subjects: 0
Study 32374868 — intervention group
Group type: COMPARATOR
Intervention: Clinical and imaging follow-up without occlusion treatment
Number of subjects: 0
Study 32374962 — intervention group
Group type: EXPERIMENTAL
Intervention: Emapalumab with dexamethasone
Number of subjects: 34
Study 32375659 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive framing of results in CSR PLSs (Trial 1)
Number of subjects: 336
Study 32375659 — intervention group
Group type: COMPARATOR
Intervention: Negative framing of results in CSR PLSs (Trial 1)
Number of subjects: 336
Study 32375659 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural frequencies for presentation of results in CSR PLSs (Trial 2)
Number of subjects: 336
Study 32375659 — intervention group
Group type: COMPARATOR
Intervention: Percentages for presentation of results in CSR PLSs (Trial 2)
Number of subjects: 336
Study 32375680 — intervention group
Group type: EXPERIMENTAL
Intervention: Spline-based models
Number of subjects: 0
Study 32375680 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard and spline-based parametric models
Number of subjects: 0
Study 32375680 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible models
Number of subjects: 0
Study 32375680 — intervention group
Group type: EXPERIMENTAL
Intervention: Goodness-of-fit scores
Number of subjects: 0
Study 32375680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard-based plots and goodness-of-fit tests
Number of subjects: 0
Study 32375690 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic tumor genomic testing
Number of subjects: 58
Study 32375700 — intervention group
Group type: EXPERIMENTAL
Intervention: 60s continuous walking performance parameters
Number of subjects: 126
Study 32375700 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait performance parameters from continuous walking
Number of subjects: 126
Study 32375779 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 102
Study 32375779 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 102
Study 32375779 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate+vigorous physical activity
Number of subjects: 102
Study 32375779 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 102
Study 32375814 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter rectal arterial chemoembolization (TRACE) with oxaliplatin and S-1 concurrent chemoradiotherapy (NATRACE-CRT)
Number of subjects: 95
Study 32375814 — intervention group
Group type: COMPARATOR
Intervention: Standard fluorouracil-based combined modality treatment (NA-CRT)
Number of subjects: 95
Study 32375872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) treatment
Number of subjects: 10
Study 32376136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with recent ATB use (n=11; 16%)
Number of subjects: 69
Study 32376136 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab without recent ATB use
Number of subjects: 69
Study 32376136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with fecal transplant (FMT) from responding RCC patients or beneficial commensals (Akkermansia muciniphila and Bacteroides salyersiae)
Number of subjects: 69
Study 32376136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with prior TKI exposure
Number of subjects: 69
Study 32376304 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD in patients on HD (group 1)
Number of subjects: 220
Study 32376304 — intervention group
Group type: COMPARATOR
Intervention: S-ICD in patients not on HD (group 2)
Number of subjects: 220
Study 32376304 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD in both groups
Number of subjects: 220
Study 32376325 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPBANG screening approach
Number of subjects: 214
Study 32376325 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable Apnea Prediction Index (MAPI)
Number of subjects: 214
Study 32376325 — intervention group
Group type: COMPARATOR
Intervention: Portable diagnostic approach
Number of subjects: 214
Study 32376325 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-quality polysomnography
Number of subjects: 214
Study 32376325 — intervention group
Group type: COMPARATOR
Intervention: Portable testing
Number of subjects: 214
Study 32376325 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPI
Number of subjects: 214
Study 32376325 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPBANG
Number of subjects: 214
Study 32376325 — intervention group
Group type: COMPARATOR
Intervention: Initial assessment with polysomnography
Number of subjects: 214
Study 32376335 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time AI-assisted detection
Number of subjects: 52
Study 32376721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab and GM-CSF in metastatic melanoma patients
Number of subjects: 51
Study 32376795 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSV23 vaccination in obese participants (BMI ≥30 kg/m2)
Number of subjects: 46
Study 32376795 — intervention group
Group type: COMPARATOR
Intervention: PPSV23 vaccination in nonobese participants (BMI 22-25 kg/m2)
Number of subjects: 46
Study 32376795 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSV23 vaccination in WT STING1 group (R232/R232)
Number of subjects: 46
Study 32376795 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSV23 vaccination in obese participants with 1 HAQ allele
Number of subjects: 46
Study 32377266 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy
Number of subjects: 21
Study 32377266 — intervention group
Group type: COMPARATOR
Intervention: Active Control Intervention
Number of subjects: 21
Study 32377266 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Number of subjects: 21
Study 32377287 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy
Number of subjects: 0
Study 32377287 — intervention group
Group type: COMPARATOR
Intervention: Outpatient clinic therapy
Number of subjects: 0
Study 32377367 — intervention group
Group type: EXPERIMENTAL
Intervention: Nationwide retrieval project for LTFU patients with chronic hepatitis C
Number of subjects: 0
Study 32377804 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sugar intake (100 kcal increase per day)
Number of subjects: 325
Study 32377804 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sugar from sweetened beverages (100 kcal)
Number of subjects: 325
Study 32377804 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sugar from milk products (100 kcal)
Number of subjects: 325
Study 32377892 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with cardiac disease (CCD)
Number of subjects: 56
Study 32377892 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 56
Study 32377963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 877
Study 32377978 — intervention group
Group type: EXPERIMENTAL
Intervention: DFP-11207, administered orally daily, doses escalating from 40 mg/m²
Number of subjects: 0
Study 32378735 — intervention group
Group type: COMPARATOR
Intervention: Antenatal PFMT
Number of subjects: 10832
Study 32378735 — intervention group
Group type: COMPARATOR
Intervention: PFMT started after delivery
Number of subjects: 10832
Study 32378735 — intervention group
Group type: COMPARATOR
Intervention: Postnatal PFMT
Number of subjects: 10832
Study 32379042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 133
Study 32379042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 133
Study 32379042 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 133
Study 32379042 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 133
Study 32379042 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 133
Study 32379297 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitors combined with MEK/ERK inhibitors
Number of subjects: 0
Study 32379297 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitors combined with WEE1/ATR inhibitors
Number of subjects: 0
Study 32379297 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitors combined with PI3K/AKT/mTOR inhibitors
Number of subjects: 0
Study 32379516 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX treatment
Number of subjects: 64
Study 32379640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (8 weekly sessions)
Number of subjects: 39
Study 32380357 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph Node Yield (LNY)
Number of subjects: 100
Study 32380357 — intervention group
Group type: EXPERIMENTAL
Intervention: LNY per neck level
Number of subjects: 100
Study 32380357 — intervention group
Group type: EXPERIMENTAL
Intervention: cN+ status
Number of subjects: 100
Study 32380357 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 100
Study 32380357 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph Node Ratio (LNR)
Number of subjects: 100
Study 32380357 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 100
Study 32380442 — intervention group
Group type: EXPERIMENTAL
Intervention: dTMS protocol for OCD
Number of subjects: 0
Study 32380442 — intervention group
Group type: EXPERIMENTAL
Intervention: dTMS protocol for MDD
Number of subjects: 0
Study 32380442 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dTMS protocols for OCD and MDD
Number of subjects: 0
Study 32380442 — intervention group
Group type: COMPARATOR
Intervention: Control group (if applicable)
Number of subjects: 0
Study 32380454 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid treatment
Number of subjects: 3441
Study 32380535 — intervention group
Group type: EXPERIMENTAL
Intervention: sAML-like gene mutations (mutations in ASXL1, SRSF2, STAG2, BCOR, U2AF1, EZH2, SF3B1, ZRSR2)
Number of subjects: 509